BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 17765191)

  • 1. Non-[18F]FDG PET in clinical oncology.
    Groves AM; Win T; Haim SB; Ell PJ
    Lancet Oncol; 2007 Sep; 8(9):822-30. PubMed ID: 17765191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
    Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
    Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical PET in oncology: not only FDG.
    Nanni C; Rubello D; Al-Nahhas A; Fanti S
    Nucl Med Commun; 2006 Sep; 27(9):685-8. PubMed ID: 16894321
    [No Abstract]   [Full Text] [Related]  

  • 5. Standardization and quantification in PET/CT imaging: tracers beyond FDG.
    Antunovic L; Rodari M; Rossi P; Chiti A
    PET Clin; 2014 Jul; 9(3):259-66. PubMed ID: 25030389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of 18F-FDG PET in oncology: clinical and resource implications.
    Al-Nahhas A; Win Z; Singh A; Khan S; Al-Sayed Y
    Nucl Med Rev Cent East Eur; 2006; 9(1):1-5. PubMed ID: 16791796
    [No Abstract]   [Full Text] [Related]  

  • 7. PET tracers in musculoskeletal disease beyond FDG.
    Wieder HA; Pomykala KL; Benz MR; Buck AK; Herrmann K
    Semin Musculoskelet Radiol; 2014 Apr; 18(2):123-32. PubMed ID: 24715445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tracers in oncology - preclinical and clinical evaluation].
    Krause BJ; Schwarzenböck S; Schwaiger M
    Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases.
    Pantaleo MA; Nannini M; Lopci E; Castellucci P; Maleddu A; Lodi F; Nanni C; Allegri V; Astorino M; Brandi G; Di Battista M; Boschi S; Fanti S; Biasco G
    Int J Oncol; 2008 Sep; 33(3):443-52. PubMed ID: 18695872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging: what can be used today.
    Jager PL; de Korte MA; Lub-de Hooge MN; van Waarde A; Koopmans KP; Perik PJ; de Vries EG
    Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S27-32. PubMed ID: 16361133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in metabolic imaging for surgical oncology.
    Iagaru A; Quon A
    Surg Oncol Clin N Am; 2007 Apr; 16(2):273-92. PubMed ID: 17560512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in urologic oncology: positron emission tomography molecular imaging.
    Bouchelouche K; Oehr P
    Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical molecular imaging with positron emission tomography.
    Saleem A; Charnley N; Price P
    Eur J Cancer; 2006 Aug; 42(12):1720-7. PubMed ID: 16797972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The next generation of positron emission tomography radiopharmaceuticals in oncology.
    Rice SL; Roney CA; Daumar P; Lewis JS
    Semin Nucl Med; 2011 Jul; 41(4):265-82. PubMed ID: 21624561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular imaging using PET for breast cancer.
    Kurihara H; Shimizu C; Miyakita Y; Yoshida M; Hamada A; Kanayama Y; Yonemori K; Hashimoto J; Tani H; Kodaira M; Yunokawa M; Yamamoto H; Watanabe Y; Fujiwara Y; Tamura K
    Breast Cancer; 2016 Jan; 23(1):24-32. PubMed ID: 25917108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET imaging of brain tumors.
    Fischman AJ
    Cancer Treat Res; 2008; 143():67-92. PubMed ID: 18619214
    [No Abstract]   [Full Text] [Related]  

  • 17. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.
    Koopmans KP; de Vries EG; Kema IP; Elsinga PH; Neels OC; Sluiter WJ; van der Horst-Schrivers AN; Jager PL
    Lancet Oncol; 2006 Sep; 7(9):728-34. PubMed ID: 16945767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The contribution of PET to radiation treatment planning].
    Belkacémi Y; Lartigau E; Kerrou K; Carpentier P; Taïeb S; Giraud P
    Bull Cancer; 2007 Jan; 94(1):99-108. PubMed ID: 17237010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitfall of (18)F-FDG-PET imaging in oncology: uterine fibromyoma.
    Tripathi M; Khurana A; D'Souza MM; Sharma R
    Hell J Nucl Med; 2009; 12(2):175-6. PubMed ID: 19675878
    [No Abstract]   [Full Text] [Related]  

  • 20. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
    Shiue CY; Welch MJ
    Radiol Clin North Am; 2004 Nov; 42(6):1033-53, viii. PubMed ID: 15488556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.